News and Events

Potential adverse drug reactions to new targeted therapies should not be underestimated

28 August 2019

This recent review analysed toxicity profiles of different agents currently used for the treatment of early and advanced melanoma. It found that new therapies are not free from the risk of causing adverse reactions, some of which must be managed promptly and appropriately; moreover the multiplicity of the metabolic pathways exposes the new target therapies to relevant potential interactions. 

Investigating strategies to improve clinical trial opportunities for patients with cancer in New Zealand—INSIGHT​

2 August 2019

Through a qualitative survey of cancer patients around New Zealand, this recent study attempted to better understand why New Zealand has low clinical trials participation rates. It found many New Zealand cancer patients are interested in being involved in clinical trials, suggesting that addressing the areas of clinician and infrastructure barriers may help improve access to clinical trials in NZ.

KEYNOTE-006: Pembrolizumab superior to ipilimumab

2 August 2019

This study presents post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study which compared Pembrolizumab to ipilimumab for the treatment of advanced melanoma (KEYNOTE-006). According to the results of the study, Pembrolizumab continued to show superiority over ipilimumab after almost 5 years of follow-up, providing further support for use of pembrolizumab in patients with advanced melanoma.

Nearly all US primary care providers report regular or occasional counseling on sun protection

27 July 2019

This recent study analysed data from the 2016 DocStyles, a web-based survey of U.S. primary care providers, to examine skin cancer prevention counseling practices among 1506 providers. Results showed nearly all providers reported regular or occasional counseling on sun protection, however lack of time, more urgent health concerns, and patient disinterest were listed as common barriers.